Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And still no one believes this BS. LMAO
It's much bigger than that. 10x bigger now and will be $13 billion in the coming years.
Most hair regrowth products only produce results for 50-70% or so of users. Not big results either. It takes many months to a year or so to get some hair back.
ALL those products DO NOT have ViaDerma's unique topical delivery system.
Still waiting to see their clinical studies, but you'd have to assume the results were exceptionally better than all the competition for them to move into high gear to get a product to market this year.
More products. More markets. More value.
LOL. Huge P & D here. Look at all that sell volume! LOL!!!
1.5m shares traded.
HALT THE STOCK! HAHAHAHA.
LMAO. There is no "pump and dump" here.
Routine and always irrelevant.
Incorrect. It will be available this year in 2023. We're in March, so technically it will be available in less than one year.
FDA-registration comes first, product launch comes next. FDA registration should be received within 90 days, yet we'll likely have word sooner.
Don't think Vitastem is going to be available to the public any time soon.
Think their focus is on larger scale B2B sales. Higher price target per product and they are not as price sensitive. Plus, according to last PR, they should be getting Vitastem approved with medicare benefits and insurers will cover most if not all the costs.
One hospital could easily buy $100K+ in product yearly.
X 6000+ hospitals - JUST in THE US > https://www.aha.org/statistics/fast-facts-us-hospitals
Then, Vitastem can also be used with...
X 9500 plastic surgeons > https://www.zippia.com/plastic-surgeon-jobs/demographics/
X 9200 dermatologists > https://www.bls.gov/oes/current/oes291213.htm
we're not even counting veterinarians, surgical centers, assisted living / nursing homes, schools & universities (nursing offices / wards).
the TAM is in the hundreds of billions - yearly!
Once pros use it, they'll see the fast results unlike anything else they've been using. After that, we'll have a growing list of very engaged customers. More orders, more word of mouth, more new and repeat orders, more word of mouth... on repeat.
2022 saw serious supply chain issues for Viaderma. During that time they were reformulating Vitastem with the new active ingredient Bacitracin (doesn't stain skin or clothes like the first generation one did) and also got around allergies a lot of people tend to have for the tetracycline version too.
They secured big shipments of the next generation Vitastem Ultra and have gone to market with sales to doctors, hospitals, wound care centers, which they have mentioned. The big focus is on B2B sales currently and with licensing their formulas too.
The hair restoration market is massive. There's a lot of players in it but all use the same product nearly. You're only buying the brand. Ex. Rogaine and now rising star, HIMS.
Viaderma has the more effective method of delivering medication to the site of need. 10,000x more than others. So, you really need to assume that their new hair product will be in the tier-1 of them all out of the gate. Marketing can help get the word out too. I'd assume this will be DTC use which opens the door to billions of buyers around the world.
Viaderma is sitting on a gold mine. And that is their transdermal technology. They can literally create dozens of their own product lines for specific industries, or license them or "white label" for other big brands too.
Their solutions target some $360 billion global markets. That's huge.
Since all their ingredients and formula seems to be FDA-registered already for Vitastem, and if much is the same for the hair product line, then it really only should take a few weeks to approve. I'm sure news updates will come soon. Hopefully April/May time.
Multiple product revenue streams. This is really good news!
Yes. Short Squeeze makes shorts need to cover their butts.
Burn them all.
Looks like a lot of short volume still needs to cover. https://www.otcshortreport.com/company/VDRM
Expect more naked short volume pressure to come.
This is just 1 licensing deal with one wound care network. There's many, many dozens of target healthcare networks in the US alone. Not to mention hundreds in CA, MX, UK, AU, Europe & Middle East, India, SE Asia, etc. too.
9 figures in licensing deals opportunities each year. Cosmetics can be a very big one too. Anti-aging, skin care, hair care, and more.
Those are just in licensing. Large wholesale hospital orders will start coming in soon this year too. The new Vitastem formula is getting great reviews and is highly effective. It should be a must have. Sell 1m bottles and that'll be like $100M+ in revenue. X 10 FPE and you have a billion+ mcap here.
Because SP drops doesn't mean it's "dilution" LOL!
It goes up & down. Relax!
New tweet. New corporate website up. More updates coming.
We're pleased to announce that the first version of our new corporate website is now live. More updates will be forthcoming. https://t.co/T06nVSspq4
— ViaDerma (@viaderma) February 23, 2023
FINRA reported. Yes, shorted.
VDRM is being shorted down and accumulated.
https://stockcharts.com/freecharts/gallery.html?VDRM
Zero proof of millions of shares being dumped on the market with "dilution"
https://www.otcshortreport.com/company/VDRM
57% short volume yesterday too.
Suspicious all around with this one.
Awful comms from the companies. Still too many unknowns.
Shorts Short Penny Stocks.
https://www.otcshortreport.com/company/VDRM
Source: Finra
2M short volume yesterday alone.
Shorts Covering Today.
Down days have had a lot of naked short selling.
Today seems like quite a bit of covering here.
https://www.otcshortreport.com/company/VDRM
LOL. Incorrect.
Going up.
Doubt it.
Small fries aren't going to hurt this stock.
To pay for the marketing agency services for 2023. The PR clearly stated that they're working with ViaDerma for 2023 to power all marketing developments.
If VDRM hired internally, the amount of bodies and budgets they would require on staff would likely run them $500K yearly at least. Competitors invest that weekly or monthly alone in marketing and brand development.
IS is incentivized to grow the business. Raising the OS doesn't mean the shares were all sold and diluted.
Check with VDRM's IR guy here on this one.
Pretty sure that the docs shares are all restricted and he can't sell unless filing the paperwork to do so.
IR guy should be able to confirm this one too for you.
LOL! This literally happens EVERY SINGLE DAY.
Late MM post.
Again, THIS IS NOT DILUTION.
LEARN. THE. GAME.
Pretty sure it's a 1 year lockup with the transfer agent / clearing house.
Even though they're labeled 'unrestricted' it doesn't mean IS is freely trading them. The shares are probably held in escrow with a clearing house or something.
As mentioned previously too, it wouldn't really make sense to sell out all the shares this low.
The IR guy should be able to confirm this or there will be a public follow up.
This looks like day trading currently or others accumulating.
RSI cooling off to oversold territory. CMF is showing increasing money flow INTO VDRM, not out. Plus, high short volume activity. This happens a lot when there is news and big rise in price.
Doesn't mean IS is dumping shares. And, why would they???
IS just signed the agreement and started last month. WHY sell this low and not realize the fruits of labor over the next year or so??
You literally have ZERO proof they're selling.
However, I just picked up another milly at the low today. I've had that limit order in for awhile now and it got filled.
See, this is how limit orders work. It doesn't mean "DILUTION!"
You also conveniently forget to mention about SHORT SELLERS!
Since the "news" came out. There's been A LOT of naked short selling.
See: https://www.otcshortreport.com/company/VDRM (source = FINRA).
LEARN THE GAME.
For literally an entire marketing team org chart to manage and scale out multi-channel marketing campaigns.
We're talking low 6 figures for multiple bodies and other marketing costs, while competitors invest 7 figures monthly in their marketing.
The doc got one hell of a deal here.
HAHAHA. It will never see those levels. Never.
Loading up shares on sale today. This is a solid load area.
Just smack the ask big guy. Show us what you got here.
You need to get your facts straight. They're not. You can confirm this with the IR guy too.
Somebody gets it.
They literally just signed and announced the contract a few weeks ago. There is ramp up time to get the websites rebranded and more. If only folks would actually read the PR, they explained everything that is going to be done this year.
There is A LOT of work in there to be done. Teams of people are required and quite a bit of capital to manage that many web channels and grow exposure and sales online too.
There is minimal dilution to the OS in the grand scheme of things here. ViaDerma literally has to compete against Neosporin and other billion dollar brands. You're not going to compete against them with hiring interns to run marketing or a couple of thousand $ a month. You need big guns to get from 0 to 1.
Like I said, patience here. I'd give this Q1 '23 here to see results, but still very confident that 2023 is going to be very special here for the company.
So is this you leaving now? Pretty please!
The issued shares have to be restricted. There is an increase in OS but shares are NOT being dumped freely on the market.
You can confirm this with the IR guy.
This is NOT dilution. You just explained it in your own words.
LOWer bids are getting filled. IF you put in a low bid (ex. .0065) and there is not super high volume, and more volume to the side of LOWer bids, they will likely get filled if/when shareholders are willing to sell and/or shorts are covering there.
Good amount of naked short selling of VDRM: https://www.otcshortreport.com/company/VDRM
Because the price goes down a little, DOES NOT mean it's "DILUTION"
Plus, there shouldn't be ANY convertible note holders left in VDRM.
These are just MMs making money up or down. That's it.
The new Bacitracin based Product has only just got to market a few months ago.
This is 10x better than the previous one.
Read this carefully...
LOS ANGELES, CALIFORNIA, UNITED STATES, January 12, 2023/ EINPresswire.com / -- ViaDerma, Inc. (OTC Pink: VDRM) is extremely pleased to announce that they have retained the global digital marketing agency leader INTENT SCIENCES to manage and scale their business growth online via branding, SEO, social media, content marketing, and more throughout 2023.
INTENT SCIENCES is a leading digital marketing agency that specializes in comprehensive go-to-market strategies, SEO (search engine optimization), CRO (conversion rate optimization), social media, press, content marketing, brand development, and more. To date, they have helped dozens of Silicon Valley & international venture-backed startups to Fortune 500 brands generate over $1 billion in revenue online. You can learn more about their comprehensive business experience here.
“We are extremely thrilled to bring on INTENT SCIENCES at this time and to help us move the business forward in this new year. We have seen their results with other companies, and we are convinced their team will greatly help us build the Vitastem brand and drastically increase our revenues for 2023 and beyond.” said ViaDerma President & CEO, Dr. Chris Otiko.
The INTENT SCIENCES marketing team will be working very closely with ViaDerma’s management to help grow the business with advanced B2B & B2C digital marketing campaigns.
Source: https://apnews.com/article/medication-ein-presswire-newsmatics-los-angeles-business-92f5b924a1219803a8e59db65c440514
Agree fully. I don't think the Dr has ill intentions here. But s#it happens in business. Delays, new testing requirements, FDA stuff, and more.
He is not a great CEO. He's a Dr and inventor of one of, if not the strongest antibiotic in the world.
The recent moves seem positive. We all want to see growth here. Deals and revenue coming in. I think this is all going to change for the better this year, but its not going to happen overnight.
New product to GTM, new brands, and marketing support for ecommerce sales and b2b is so important. Finally they've taken steps to get this in place. Although it is very early in the process, good stuff will come.
They also had to completely overhaul and reformulate Vitastem to have main ingredient Bacitracin (much more widely accepted globally). That held all their deals up for the past year and could not sell until testing and approvals were met.
They were and got a TON of inventory in back in September as they'd mentioned.
Deals should start flowing again. :)
Yes. They "retained" IS.
For that to be news, there is a contract in place. NO ONE would PR something like that without a contract.
The PR would have said LOI or something else...
Looks like the plan is to have new websites and more out this month.
I'm sure a lot of news will follow too.
That is exactly what IS focuses on.
SEO & CRO as it says on the website.
Forgot to mention that they've driven over $1 Billion in revenue online for startups to fortune 500 brands.
They don't have to be "big" to be powerful.
There is A LOT of work that needs to be done.
Everyone here knows it. Positive steps are being taken. But, you can't build Rome overnight.
I would remain patient here in Q1 '23. There will be a lot of good things coming here from the company. But, it takes some time to revamp their websites, the SEO work, new content, social media, and more as well that is in the PR that will be worked on.
2023 is a big year for change and growth, but I think that 2024 will be something to remember forever here. Especially when they have this year to really start scaling the business online and offline with B2B sales too.
If shareholders really want to see the best results from this company. Ask yourself what YOU can do to help them! Ask the company too.
But, when all the new stuff comes out, hopefully shareholders will be sharing everything they publish on their social media profiles and even better - ask for and even recommend Vitastem to your primary care doctors, dermatologists, school nurses, and more. But also make sure to BUY the product and review it too.
Hell, contact CVS, Walgreens, Kroger, Publix, Albertsons, Safeway, Wegmans, Sprouts, Boots, etc, and all the big brand retailers who could carry Vitastem and ask them why they don't have it?! It's far superior to Neosporin or other antibiotics (according to all their testing results).
Just a few minutes of your time each week or month can have a profound effect on getting more visibility on the brand. In turn, more sales will come and good financials to follow. Then, an increase in share price will come too.
We can all band together and really help here. We're all essentially on the ground floor of this company that can and will be a huge success story.
Long & Strong. Let's do this!
Pretty sure this is the case. The shares are restricted for likely 1 year.
Dr O's shares are all restricted I believe and he cannot sell them when he feels. He has to wait for acquisition or likely need to file paperwork that he plans to sell, or if he does, he may need to file it within a day or so.
There is no dilution going on. No convertible notes being converted to cash. Just FUD by a few on here.
There have been lower limit orders getting filled. That's it.
Limit Orders Filled.
How do you I know this? Because I just scooped a bunch more up at those prices.
BID ORDERS FILLED is NOT DILUTION.
#TheMoreYouKnow